Anavex Life Sciences (AVXL) said Thursday that its phase 2 clinical study of Anavex 3-71 for the treatment of schizophrenia has completed enrollment with a total of 71 participants.
The company said 16 of those participants are in part A of the study, which investigated multiple ascending doses and has been completed with "encouraging" initial safety and electroencephalography biomarker results.
The rest of the participants are in part B, which includes a longer treatment duration and will give more clinical and biomarker data on the efficacy and safety of the treatment, the company said.
Anavex said it expects to release topline data from the study in H2.
Price: 9.37, Change: -0.13, Percent Change: -1.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.